pyrazines has been researched along with panobinostat in 24 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (12.50) | 29.6817 |
2010's | 21 (87.50) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Anderson, KC; Atadja, P; Catley, L; Chauhan, D; Hideshima, T; Kiziltepe, T; Munshi, NC; Neri, P; Tai, YT; Tassone, P; Weisberg, E | 1 |
Atadja, P; Carvajal-Vergara, X; Gutiérrez, N; López-Pérez, R; Maiso, P; Mateo, G; Ocio, EM; Pandiella, A; San Miguel, JF | 1 |
Adjei, AA; Atadja, P; Friday, BB; Sarkaria, J; Wigle, D; Yang, L; Yu, C | 1 |
Atadja, P; Crusoe, E; de Alava, E; Fernández-Lázaro, D; Garayoa, M; Hernández-Iglesias, T; Maiso, P; Ocio, EM; Pandiella, A; San-Miguel, JF; San-Segundo, L; Shao, W; Vilanova, D; Yao, YM | 1 |
Goldschmidt, H; Ho, AD; Schmitt, S | 1 |
Atadja, P; Balusu, R; Bhalla, KN; Buckley, KM; Coothankandaswamy, V; Fiskus, W; Ha, K; Joshi, A; Nalluri, S; Rao, R; Savoie, A; Sotomayor, E; Tao, J | 1 |
Ghobrial, IM; Roccaro, AM; Sacco, A | 1 |
Bansal, R; Boise, LH; Fink, EE; Hu, Q; Lee, KP; Liu, S; Mannava, S; Moparthy, KC; Nair, JR; Nikiforov, MA; Wawrzyniak, JA; Zhuang, D; Zucker, SN | 1 |
Abonour, R; Anderson, KC; Bengoudifa, BR; Bourquelot, PM; de Magalhaes-Silverman, M; Goldschmidt, H; Hazell, K; Lonial, S; Matous, J; Siegel, D; Vij, R; Wolf, JL | 1 |
Chen, WW; Huang, KK; Huang, M; Jiang, XJ; Meng, FY; Wang, Q; Wang, ZX; Wu, FQ; Zhou, HS | 1 |
Cao, Q; Dudek, AZ; Wang, H | 1 |
Ang, AL; Goh, YT; Mok, SJ; Phipps, C; Tan, D | 1 |
Huang, KK; Jiang, XJ; Meng, FY; Qiao, L; Wang, Q; Wang, ZX; Wu, FQ; Yang, M; Ye, JY; Yi, ZS; Zhao, QX; Zhou, HS | 1 |
Chang, MX; Jia, G; Lu, H; Lu, YJ; Ma, YP; Zhang, L | 1 |
Jia, G; Ma, YP; Zhang, L | 1 |
Alsina, M; Coutre, SE; Gasparetto, C; Khan, M; Lonial, S; Mukhopadhyay, S; Ondovik, MS; Paley, CS; Richardson, PG; Schlossman, RL; Weber, DM | 1 |
Anderson, KC; Bladé, J; Bourquelot, PM; Günther, A; LeBlanc, R; Mishra, KK; Mu, S; Richardson, PG; San-Miguel, JF; Sezer, O; Siegel, D; Sopala, M; Sutherland, H; Victoria Mateos, M | 1 |
Buck, SA; Caldwell, JT; Edwards, H; Ge, Y; Qing, WY; Taub, JW; Wang, G; Wang, Z | 1 |
Angelucci, E; Annese, T; Berardi, S; Caivano, A; Catacchio, I; Dammacco, F; De Luisi, A; Derudas, D; Ditonno, P; Frassanito, MA; Guarini, A; Minoia, C; Moschetta, M; Nico, B; Piccoli, C; Ria, R; Ribatti, D; Ruggieri, S; Ruggieri, V; Vacca, A | 1 |
Iida, S; Ri, M | 1 |
Asano, T; Isono, M; Ito, K; Sato, A | 1 |
Beksac, M; Bengoudifa, BR; Binlich, F; Bladé, J; Cavenagh, JD; Chen, W; Chuncharunee, S; Corradini, P; Corrado, C; de la Rubia, J; Dimopoulos, MA; Einsele, H; Elghandour, A; Gimsing, P; Günther, A; Hou, J; Hungria, VT; Jedrzejczak, WW; Kaufman, JL; LeBlanc, R; Lee, JH; Lee, JJ; Lonial, S; Moreau, P; Nahi, H; Nakorn, TN; Numbenjapon, T; Ocio, EM; Pulini, S; Qiu, L; Richardson, PG; Salwender, H; San-Miguel, JF; Schlossman, RL; Shelekhova, T; Siritanaratkul, N; Sohn, SK; Sopala, M; Tan, D; Veskovski, L; Wang, MC; Warzocha, K; White, D; Yong, K; Yoon, SS | 1 |
Chandra, J; Corrales-Medina, FF; Manton, CA; Orlowski, RZ | 1 |
Fenichel, MP | 1 |
2 review(s) available for pyrazines and panobinostat
Article | Year |
---|---|
Anti-angiogenic therapies in the treatment of Waldenstrom's Macroglobulinemia.
Topics: Angiogenesis Inhibitors; Bone Marrow; Boronic Acids; Bortezomib; Endothelial Cells; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Panobinostat; Protease Inhibitors; Proteasome Inhibitors; Protein Kinase C; Pyrazines; TOR Serine-Threonine Kinases; Tumor Microenvironment; Waldenstrom Macroglobulinemia | 2011 |
[Determinants of sensitivity to proteasome inhibitors and strategies to overcome acquired resistance to bortezomib in multiple myeloma].
Topics: Activating Transcription Factor 3; Activating Transcription Factor 4; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclin-Dependent Kinase 5; Cytokines; Dexamethasone; DNA-Binding Proteins; Drug Discovery; Drug Resistance, Neoplasm; Humans; Hydroxamic Acids; Indoles; Kruppel-Like Transcription Factors; Molecular Targeted Therapy; Multiple Myeloma; Nicotinamide Phosphoribosyltransferase; Oligopeptides; Panobinostat; Phosphorylcholine; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Regulatory Factor X Transcription Factors; Toyocamycin; Transcription Factors | 2014 |
5 trial(s) available for pyrazines and panobinostat
Article | Year |
---|---|
Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Boronic Acids; Bortezomib; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Lenalidomide; Male; Metabolic Clearance Rate; Middle Aged; Multiple Myeloma; Nausea; Neutropenia; Panobinostat; Pyrazines; Recurrence; Remission Induction; Thalidomide; Thrombocytopenia; Treatment Outcome | 2012 |
Phase II study of panobinostat and bortezomib in patients with pancreatic cancer progressing on gemcitabine-based therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Hydroxamic Acids; Indoles; Male; Middle Aged; Pancreatic Neoplasms; Panobinostat; Pyrazines | 2012 |
PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Humans; Hydroxamic Acids; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Panobinostat; Pyrazines | 2013 |
Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Hydroxamic Acids; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Panobinostat; Pyrazines | 2013 |
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hydroxamic Acids; Indoles; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Panobinostat; Prognosis; Pyrazines; Remission Induction; Survival Analysis; Treatment Outcome | 2014 |
17 other study(ies) available for pyrazines and panobinostat
Article | Year |
---|---|
Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells.
Topics: Boronic Acids; Bortezomib; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydrolases; Hydroxamic Acids; Indoles; Multiple Myeloma; Panobinostat; Poly(ADP-ribose) Polymerase Inhibitors; Protease Inhibitors; Pyrazines; Tubulin; Tubulin Modulators; Tumor Cells, Cultured | 2006 |
The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.
Topics: Acetylation; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Dexamethasone; Drug Resistance, Neoplasm; Drug Synergism; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Indoles; Melphalan; Multiple Myeloma; Panobinostat; Pyrazines | 2006 |
Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Boronic Acids; Bortezomib; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Electrophoresis, Polyacrylamide Gel; Enzyme Inhibitors; Glioma; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Mitochondria; Panobinostat; Proteasome Inhibitors; Protein Transport; Pyrazines; RNA, Small Interfering | 2008 |
In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Cells, Cultured; Dexamethasone; Disease Models, Animal; Humans; Hydroxamic Acids; Indoles; Lenalidomide; Mice; Mice, SCID; Multiple Myeloma; Panobinostat; Pyrazines; Random Allocation; Thalidomide; Xenograft Model Antitumor Assays | 2010 |
The oral histone deacetylase inhibitor LBH589 is a potential and promising therapeutic agent in multiple myeloma after at least two lines of chemotherapy including bortezomib or lenalidomide.
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Feasibility Studies; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Lenalidomide; Multiple Myeloma; Panobinostat; Pyrazines; Thalidomide; Treatment Failure; Treatment Outcome | 2010 |
Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells.
Topics: Acetylation; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Endoplasmic Reticulum; Fluorescent Antibody Technique; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Indoles; Lymphoma, Mantle-Cell; Mice; Microscopy, Confocal; Panobinostat; Protein Folding; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Stress, Physiological; Survival Rate; Transcription Factor CHOP; Xenograft Model Antitumor Assays | 2010 |
KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Indoles; Kruppel-Like Transcription Factors; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Panobinostat; Promoter Regions, Genetic; Protein Binding; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Transcription Factors | 2012 |
[Reversal effect of LBH589 alone or in combination with bortezomib on drug-resistance in myeloid leukemia and its mechanism].
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; HL-60 Cells; Humans; Hydroxamic Acids; Indoles; Leukemia, Myeloid; Panobinostat; Pyrazines; Signal Transduction | 2011 |
Bortezomib and panobinostat combination is effective against PTCL.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Hydroxamic Acids; Indoles; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Multimodal Imaging; Panobinostat; Positron-Emission Tomography; Pyrazines; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Synergistic effect of panobinostat and bortezomib on chemoresistant acute myelogenous leukemia cells via AKT and NF-κB pathways.
Topics: Acetylation; Antineoplastic Agents; Boronic Acids; Bortezomib; Caspases; Drug Resistance, Neoplasm; Drug Synergism; HL-60 Cells; Humans; Hydroxamic Acids; Indoles; Leukemia, Myeloid, Acute; NF-kappa B; Panobinostat; Poly(ADP-ribose) Polymerases; Proteolysis; Proto-Oncogene Proteins c-akt; Pyrazines | 2012 |
[Inhibitory effect of histone deacetylase inhibitor LBH589 on multiple myeloma MM1R cells in vitro].
Topics: Acetylation; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Multiple Myeloma; Panobinostat; Pyrazines | 2012 |
[Study on histone deacetylase inhibitor LBH589 induces apoptosis of multiple myeloma cells and its reversal of drug resistance mechanism].
Topics: Acetylation; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Multiple Myeloma; Panobinostat; Pyrazines | 2012 |
Panobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Etoposide; G2 Phase Cell Cycle Checkpoints; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Neuroblastoma; Panobinostat; Phenylurea Compounds; Protein Kinases; Pyrazines | 2013 |
HIF-1α of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Endothelial Cells; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Panobinostat; Proteome; Pyrazines; Reactive Oxygen Species; Thalidomide; Transcription, Genetic | 2014 |
Panobinostat synergizes with bortezomib to induce endoplasmic reticulum stress and ubiquitinated protein accumulation in renal cancer cells.
Topics: Acetylation; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Disease Models, Animal; Drug Synergism; Endoplasmic Reticulum Stress; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Indoles; Kidney Neoplasms; Mice, Inbred BALB C; Panobinostat; Pyrazines; Ubiquitinated Proteins | 2014 |
Efficacy of panobinostat and marizomib in acute myeloid leukemia and bortezomib-resistant models.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Caspases; Cell Proliferation; Drug Combinations; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Hydroxamic Acids; Indoles; Lactones; Leukemia, Myeloid, Acute; Panobinostat; Proteasome Inhibitors; Pyrazines; Pyrroles; Tumor Cells, Cultured | 2015 |
FDA approves new agent for multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Drug Approval; Drug Resistance, Neoplasm; Humans; Hydroxamic Acids; Indoles; Multiple Myeloma; Oligopeptides; Panobinostat; Pyrazines; Treatment Outcome; United States; United States Food and Drug Administration | 2015 |